Michael Tung's questions to WINDTREE THERAPEUTICS INC /DE/ (WINT) leadership • Q4 2014
Question
Michael Tung of Partner Investments asked for details on clinical indicators from the AEROSURF trial, specifically if there was a difference in the time until babies required a ventilator between the treatment and control groups. He also sought to confirm the timeline for the release of the full data set.
Answer
Chief Development Officer Steven Simonson confirmed that for babies who required intubation, the time to that intervention has been prolonged in the AEROSURF-treated groups as the dose has increased. He assured that this data would be detailed in the final report. CEO John Cooper reiterated the company's expectation to release the full data in the early second quarter of 2015.